Agios Pharmaceuticals will present their latest quarterly figures on May 2.Wall Street predict expect Agios Pharmaceuticals will report losses ...

May 14, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that data from ...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript May 2, 2024 Agios Pharmaceuticals, Inc. isn’t one ...

Cantor Fitzgerald raised the price target for the Agios Pharmaceuticals Inc (NASDAQ:AGIO) stock to “an Overweight”. The rating was released on February 08, 2024, according to finviz. The research ...

May 02, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today reported business ...

The Pontian Society of Sydney Panagia Soumela is marking its 60th anniversary with a gift to the church of Agios Stefanos, ...

Cash Position: Ended Q1 2024 with $714.3 million in cash, cash equivalents, and marketable securities, down from $806.4 ...

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat ...

Particularly noisy was the first Resurrection at Agios Konstantinos Omonia, with the priest scattering laurel leaves to the ...

Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.45 per share versus the Zacks Consensus Estimate of a loss of $1.64. This compares to loss of $1.47 per share a year ago.

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary Vandana ...